Eli Lilly Paying Up To $202M In Genetic Medicine Deal
Eli Lilly and Co. has agreed to acquire privately held Engage Biologics Inc., which is developing a delivery technology for genetic medicines, in a deal worth up to $202 million, Cooley...To view the full article, register now.
Already a subscriber? Click here to view full article